OLD National Bancorp IN Has $772,000 Holdings in AstraZeneca PLC (NASDAQ:AZN)

OLD National Bancorp IN lifted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 22.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,463 shares of the company’s stock after purchasing an additional 2,113 shares during the period. OLD National Bancorp IN’s holdings in AstraZeneca were worth $772,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Anchor Investment Management LLC acquired a new position in shares of AstraZeneca during the fourth quarter worth approximately $26,000. Compagnie Lombard Odier SCmA bought a new stake in AstraZeneca in the fourth quarter valued at approximately $27,000. Nemes Rush Group LLC increased its stake in AstraZeneca by 375.6% in the third quarter. Nemes Rush Group LLC now owns 428 shares of the company’s stock valued at $29,000 after purchasing an additional 338 shares in the last quarter. LWM Advisory Services LLC bought a new stake in AstraZeneca in the third quarter valued at approximately $35,000. Finally, Arlington Trust Co LLC bought a new stake in AstraZeneca in the fourth quarter valued at approximately $37,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

Shares of AZN stock opened at $70.85 on Wednesday. The stock has a market cap of $219.67 billion, a P/E ratio of 36.90, a P/E/G ratio of 1.29 and a beta of 0.50. The company has a debt-to-equity ratio of 0.57, a current ratio of 0.82 and a quick ratio of 0.64. The company has a fifty day moving average price of $66.62 and a two-hundred day moving average price of $65.92. AstraZeneca PLC has a one year low of $60.47 and a one year high of $76.56.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Thursday, February 8th. The company reported $0.73 EPS for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.01). The firm had revenue of $12.02 billion during the quarter, compared to analyst estimates of $12.07 billion. AstraZeneca had a net margin of 13.00% and a return on equity of 30.19%. The business’s revenue was up 7.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.69 EPS. As a group, equities analysts predict that AstraZeneca PLC will post 4 EPS for the current year.

AstraZeneca Increases Dividend

The business also recently announced a Semi-Annual dividend, which was paid on Monday, March 25th. Stockholders of record on Friday, February 23rd were paid a dividend of $0.965 per share. This represents a dividend yield of 2.3%. The ex-dividend date was Thursday, February 22nd. This is a boost from AstraZeneca’s previous Semi-Annual dividend of $0.47. AstraZeneca’s dividend payout ratio (DPR) is currently 100.52%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Morgan Stanley assumed coverage on shares of AstraZeneca in a research report on Tuesday, January 23rd. They set an “overweight” rating for the company. Jefferies Financial Group cut shares of AstraZeneca from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, April 16th. Three research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, AstraZeneca currently has an average rating of “Moderate Buy” and an average target price of $80.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.